These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 24073274)

  • 21. Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy.
    Zhang J; Jin S; Guo X; Qian W
    J Int Med Res; 2018 Nov; 46(11):4418-4426. PubMed ID: 30226089
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TSP1-CD47-SIRPα signaling facilitates the development of endometriosis by mediating the survival of ectopic endometrium.
    Liu Y; Li M; Wei C; Tang L; Sheng Y; Liu Y; Li D; Ding D; Qiu J; Zhu X
    Am J Reprod Immunol; 2020 Jun; 83(6):e13236. PubMed ID: 32196807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual regulation of SIRPalpha phosphorylation by integrins and CD47.
    Johansen ML; Brown EJ
    J Biol Chem; 2007 Aug; 282(33):24219-30. PubMed ID: 17584740
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
    Miller TW; Amason JD; Garcin ED; Lamy L; Dranchak PK; Macarthur R; Braisted J; Rubin JS; Burgess TL; Farrell CL; Roberts DD; Inglese J
    PLoS One; 2019; 14(7):e0218897. PubMed ID: 31276567
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signal-regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(-) hematopoietic cells.
    Seiffert M; Brossart P; Cant C; Cella M; Colonna M; Brugger W; Kanz L; Ullrich A; Bühring HJ
    Blood; 2001 May; 97(9):2741-9. PubMed ID: 11313266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelin down-regulates myelin phagocytosis by microglia and macrophages through interactions between CD47 on myelin and SIRPα (signal regulatory protein-α) on phagocytes.
    Gitik M; Liraz-Zaltsman S; Oldenborg PA; Reichert F; Rotshenker S
    J Neuroinflammation; 2011 Mar; 8():24. PubMed ID: 21401967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of cis dimerization of signal regulatory protein alpha (SIRPalpha) in binding to CD47.
    Lee WY; Weber DA; Laur O; Stowell SR; McCall I; Andargachew R; Cummings RD; Parkos CA
    J Biol Chem; 2010 Dec; 285(49):37953-63. PubMed ID: 20826801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions.
    Baumann N; Rösner T; Jansen JHM; Chan C; Marie Eichholz K; Klausz K; Winterberg D; Müller K; Humpe A; Burger R; Peipp M; Schewe DM; Kellner C; Leusen JHW; Valerius T
    Cancer Sci; 2021 Aug; 112(8):3029-3040. PubMed ID: 34058788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
    Tahk S; Vick B; Hiller B; Schmitt S; Marcinek A; Perini ED; Leutbecher A; Augsberger C; Reischer A; Tast B; Humpe A; Jeremias I; Subklewe M; Fenn NC; Hopfner KP
    J Hematol Oncol; 2021 Sep; 14(1):155. PubMed ID: 34579739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The potentiating effect of hTFPI in the presence of hCD47 reduces the cytotoxicity of human macrophages.
    Jung SH; Hwang JH; Kim SE; Young Kyu K; Park HC; Lee HT
    Xenotransplantation; 2017 May; 24(3):. PubMed ID: 28393401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surfactant protein D (Sp-D) binds to membrane-proximal domain (D3) of signal regulatory protein α (SIRPα), a site distant from binding domain of CD47, while also binding to analogous region on signal regulatory protein β (SIRPβ).
    Fournier B; Andargachew R; Robin AZ; Laur O; Voelker DR; Lee WY; Weber D; Parkos CA
    J Biol Chem; 2012 Jun; 287(23):19386-98. PubMed ID: 22511785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system.
    Okazawa H; Motegi S; Ohyama N; Ohnishi H; Tomizawa T; Kaneko Y; Oldenborg PA; Ishikawa O; Matozaki T
    J Immunol; 2005 Feb; 174(4):2004-11. PubMed ID: 15699129
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is CD47 an innate immune checkpoint for tumor evasion?
    Liu X; Kwon H; Li Z; Fu YX
    J Hematol Oncol; 2017 Jan; 10(1):12. PubMed ID: 28077173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD47/SIRPα axis: bridging innate and adaptive immunity.
    van Duijn A; Van der Burg SH; Scheeren FA
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35831032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A SIRPα-Fc fusion protein enhances the antitumor effect of oncolytic adenovirus against ovarian cancer.
    Huang Y; Lv SQ; Liu PY; Ye ZL; Yang H; Li LF; Zhu HL; Wang Y; Cui LZ; Jiang DQ; Hao FY; Xu HM; Jin HJ; Qian QJ
    Mol Oncol; 2020 Mar; 14(3):657-668. PubMed ID: 31899582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.
    Willingham SB; Volkmer JP; Gentles AJ; Sahoo D; Dalerba P; Mitra SS; Wang J; Contreras-Trujillo H; Martin R; Cohen JD; Lovelace P; Scheeren FA; Chao MP; Weiskopf K; Tang C; Volkmer AK; Naik TJ; Storm TA; Mosley AR; Edris B; Schmid SM; Sun CK; Chua MS; Murillo O; Rajendran P; Cha AC; Chin RK; Kim D; Adorno M; Raveh T; Tseng D; Jaiswal S; Enger PØ; Steinberg GK; Li G; So SK; Majeti R; Harsh GR; van de Rijn M; Teng NN; Sunwoo JB; Alizadeh AA; Clarke MF; Weissman IL
    Proc Natl Acad Sci U S A; 2012 Apr; 109(17):6662-7. PubMed ID: 22451913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SIRPα-Fc fusion protein IMM01 exhibits dual anti-tumor activities by targeting CD47/SIRPα signal pathway via blocking the "don't eat me" signal and activating the "eat me" signal.
    Yu J; Li S; Chen D; Liu D; Guo H; Yang C; Zhang W; Zhang L; Zhao G; Tu X; Peng L; Liu S; Bai X; Song Y; Jiang Z; Zhang R; Tian W
    J Hematol Oncol; 2022 Nov; 15(1):167. PubMed ID: 36384978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.